CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction
← catalyst calendarNCT06258447 · readout in 225 d
Sponsored by BioCardia, Inc. (industry) · BCDA — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
250estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-01 | actual | When the study began enrolling |
| Primary completion | 2027-04-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-04-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ischemic Heart Failure
Intervention
- Device: Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system
Primary outcome
what the primary-completion date above is the date OFPrimary Efficacy Endpoint
measured Follow-up duration at endpoint analysis ranges from a minimum of 12 to a maximum of 24 months
Permalink · BCDA's whole pipeline · Catalyst calendar · Every registered study · What changed